{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:27:22Z","timestamp":1782178042329,"version":"3.54.5"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jjcc.2016.10.019","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T10:30:43Z","timestamp":1483093843000},"page":"501-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Emerging roles of sodium\u2013glucose cotransporter 2 inhibitors in cardiology"],"prefix":"10.1016","volume":"69","author":[{"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2016.10.019_bib0430","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archinte.167.9.921","article-title":"Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients","volume":"167","author":"Bethel","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0435","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0440","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0445","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0450","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","article-title":"Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study","volume":"28","author":"Ohkubo","year":"1995","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0455","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0460","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0465","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0470","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0475","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0480","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes","volume":"372","author":"Hayward","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0485","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0490","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrcardio.2010.35","article-title":"Intensive glycemic control and cardiovascular disease: an update","volume":"7","author":"Brown","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0495","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1463-1326.2010.01199.x","article-title":"The effect of intensive glycaemic control on cardiovascular outcomes","volume":"12","author":"Hill","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0500","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2337\/dc09-2082","article-title":"Hypoglycemia, diabetes, and cardiovascular events","volume":"33","author":"Desouza","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0505","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0510","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0515","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0520","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.clinthera.2011.04.025","article-title":"Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes","volume":"33","author":"Dailey","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0525","series-title":"Treatment guide for diabetes 2016\u20132017","author":"The Japan Diabetes Society","year":"2016"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0530","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0535","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0540","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0545","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0550","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0555","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0560","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0565","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(14)60794-7","article-title":"Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes","volume":"383","author":"Holman","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0570","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2337\/dc15-2237","article-title":"Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess?","volume":"39","author":"Smith","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0575","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0580","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0585","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0590","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0595","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.clinthera.2014.10.009","article-title":"Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?","volume":"36","author":"Clifton","year":"2014","journal-title":"Clin Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.jjcc.2016.10.019_bib0600","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.2337\/dcS15-3009","article-title":"Is the use of DPP-4 inhibitors associated with an increased risk for heart failure? Lessons from EXAMINE, SAVOR-TIMI 53, and TECOS","volume":"39","author":"Schernthaner","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0605","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0610","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0615","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0620","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0625","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0630","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.ajkd.2008.12.031","article-title":"Glucose control by the kidney: an emerging target in diabetes","volume":"53","author":"Marsenic","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0635","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0640","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0645","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cmet.2016.02.019","article-title":"Sodium intake regulates glucose homeostasis through the PPARdelta\/adiponectin-mediated SGLT2 pathway","volume":"23","author":"Zhao","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0650","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium\u2013glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocrine Rev"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0655","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0660","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0665","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14656566.2016.1145668","article-title":"Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): interim results of a post-marketing surveillance study","volume":"17","author":"Terauchi","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0670","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0675","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1475-2840-13-102","article-title":"Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)","volume":"13","author":"Zinman","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0680","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0685","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0690","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw110","article-title":"Sodium\u2013glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus","author":"Marx","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0695","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","article-title":"Sodium\u2013glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis","volume":"89","author":"Rajasekeran","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium\u2013glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0705","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0710","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.ajkd.2014.02.010","article-title":"Sodium\/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes","volume":"64","author":"De Nicola","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0715","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/ki.2013.451","article-title":"Sodium\u2013glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?","volume":"86","author":"Gilbert","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0720","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium\u2013glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0725","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0730","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","article-title":"The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes","volume":"59","author":"Cherney","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0735","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0740","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0745","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0750","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0755","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1479164115616901","article-title":"Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus","volume":"13","author":"Neeland","year":"2016","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0760","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dom.12439","article-title":"Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus","volume":"17","author":"Davies","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0765","doi-asserted-by":"crossref","first-page":"542042","DOI":"10.1155\/2012\/542042","article-title":"Sodium\u2013glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats","volume":"2012","author":"Osorio","year":"2012","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0770","doi-asserted-by":"crossref","first-page":"e0143396","DOI":"10.1371\/journal.pone.0143396","article-title":"Amelioration of hyperglycemia with a sodium\u2013glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice","volume":"10","author":"Terasaki","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0785","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12933-016-0449-7","article-title":"Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study","volume":"15","author":"Tanaka","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0790","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.12578","article-title":"Energy balance and metabolic changes with sodium\u2013glucose co-transporter 2 inhibition","volume":"18","author":"Rajeev","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0795","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0800","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jcjd.2016.02.006","article-title":"Pharmacologic management of type 2 diabetes: 2016 interim, update","volume":"40","year":"2016","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0805","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0810","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/dom.12261","article-title":"Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes","volume":"16","author":"Dziuba","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0815","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium\u2013glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0830","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12933-016-0419-0","article-title":"Research into the effect of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design","volume":"15","author":"Singh","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2016.10.019_bib0835","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-016-0381-x","article-title":"Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial","volume":"15","author":"Tanaka","year":"2016","journal-title":"Cardiovasc Diabetol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508716302970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508716302970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:56:36Z","timestamp":1760273796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508716302970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0914508716302970"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2016.10.019","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging roles of sodium\u2013glucose cotransporter 2 inhibitors in cardiology","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2016.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}